Myovant Sciences Ltd. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-03-10: Form 8-K; Period of report 2023-03-10; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 2.01.
- 2023-03-01: Form 8-K; Period of report 2023-03-01; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2023-01-26: Form 8-K; Period of report 2023-01-26; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-10-26: Form 8-K; Period of report 2022-10-26; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-03-10 | 8-K | 2023-03-10 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 2.01 The information set forth in the Introductory Note and in Items 3.03, 5.01, 5.02, 5.03 and 8.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.01 The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01. 3.03 The information set forth in the Introductory Note and under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. 5.01 The information set forth in the Introductory Note and the information set forth under Items 2.01, 3.03 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. 5.02 The information set forth in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. 5.03 The information set forth in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03. 8.01 On March 10, 2023, the Company, Sumitovant and Sumitomo issued a joint press release announcing the consummation of the Merger. | ny20008100x2_8k.htm |
| 2023-03-01 | 8-K | 2023-03-01 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On March 1, 2023, Myovant Sciences Ltd., a Bermuda exempted company limited by shares (the “Company”), held a special general meeting of shareholders (the “Special General Meeting”) to vote on the proposals described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 23, 2023. | brhc10048987_8k.htm |
| 2023-01-26 | 8-K | 2023-01-26 | 2.02 Results of Operations and Financial Condition | 2.02 On January 26, 2023, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended December 31, 2022, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20230126.htm |
| 2022-10-26 | 8-K | 2022-10-26 | 2.02 Results of Operations and Financial Condition | 2.02 On October 26, 2022, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended September 30, 2022, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20221026.htm |
| 2022-10-24 | 8-K | 2022-10-23 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On October 23, 2022, Myovant and Sumitovant issued a joint press release announcing the entry into the Merger Agreement. | ny20005635x1_8k.htm |
| 2022-10-21 | 8-K | 2022-10-21 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On October 21, 2022, Myovant Sciences Ltd. (the “Company”) held its 2022 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. | brhc10043162_8k.htm |
| 2022-10-03 | 8-K | 2022-09-30 | 8.01 Other Events | 8.01 On October 2, 2022, Myovant Sciences Ltd. (the “Company”) issued a press release announcing the receipt of a preliminary, non-binding proposal, dated September 30, 2022, from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. (collectively, “Sumitomo”) to acquire the remaining shares of the Company that Sumitomo does not currently hold. | d403495d8k.htm |
| 2022-07-27 | 8-K | 2022-07-27 | 2.02 Results of Operations and Financial Condition | 2.02 On July 27, 2022, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended June 30, 2022, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20220727.htm |
| 2022-05-10 | 8-K | 2022-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2022, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months and full fiscal year ended March 31, 2022, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20220510.htm |
| 2022-03-25 | 8-K | 2022-03-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 22, 2022, the Compensation Committee of Myovant’s board of directors adopted the first amendment to the Myovant Sciences Ltd. 2020 Inducement Plan (the “First Amendment”), which, subject to the adjustment provisions thereof, increased the authorized shares of Myovant’s common shares for issuance from 1,000,000 to 2,000,000 under the 2020 Inducement Plan. | brhc10035689_8k.htm |
| 2022-01-26 | 8-K | 2022-01-26 | 9.01 Financial Statements and Exhibits | 9.01 Exhibit No. Description 99.1 Press Release of Myovant Sciences Ltd., dated January 26, 2022, “Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates.” 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | myov-20220126.htm |
| 2022-01-10 | 8-K | 2022-01-10 | 2.02 Results of Operations and Financial Condition | 2.02 On January 10, 2022, Myovant Sciences Ltd. (“Myovant”) issued a press release announcing its preliminary unaudited financial results for the fiscal quarter ended December 31, 2021, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20220110.htm |
| 2021-11-08 | 8-K | 2021-11-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As previously announced, Ms. Kathleen Sebelius did not stand for re-election at the 2021 Annual General Shareholder Meeting of Myovant Sciences Ltd. (the “Company”). 5.07 On November 5, 2021, the Company held its 2021 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. | brhc10030481_8k.htm |
| 2021-10-26 | 8-K | 2021-10-26 | 2.02 Results of Operations and Financial Condition | 2.02 On October 26, 2021, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended September 30, 2021, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20211026.htm |
| 2021-08-12 | 8-K | 2021-08-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective August 12, 2021, Uneek Mehra entered into an Employment Agreement with Myovant Sciences, Inc. (“Myovant”), a wholly-owned subsidiary of Myovant Sciences Ltd. (the “Company”), pursuant to which he will join Myovant on or about September 7, 2021 as Chief Financial and Business Officer and in that role will also serve as the Company’s principal financial and accounting officer. | brhc10027981_8k.htm |
| 2021-07-28 | 8-K | 2021-07-28 | 2.02 Results of Operations and Financial Condition | 2.02 On July 28, 2021, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended June 30, 2021, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20210728.htm |
| 2021-07-07 | 8-K | 2021-07-06 | 8.01 Other Events | 8.01 On July 6, 2021, Myovant Sciences GmbH, a subsidiary of Myovant Sciences Ltd., submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for once-daily MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. | brhc10026275_8k.htm |
| 2021-06-04 | 8-K | 2021-06-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 1, 2021, Ms. Kathleen Sebelius notified the board of directors (the “Board”) of Myovant Sciences Ltd. of her intention to retire from service on the Board upon expiration of her current term, and therefore, that she will not stand for re-election to the Board at Myovant’s annual general meeting of shareholders to be held in 2021. | brhc10025465_8k.htm |
| 2021-05-26 | 8-K | 2021-05-26 | 8.01 Other Events | 8.01 On May 26, 2021, the United States (U.S.) Food and Drug Administration approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), indicated for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. | brhc10025204_8k.htm |
| 2021-05-19 | 8-K | 2021-05-19 | 8.01 Other Events | 8.01 On May 18, 2021, the U.S. Food and Drug Administration (FDA) informed Myovant by teleconference that they have placed a partial clinical hold on the Phase 3 SERENE study (MVT-601-050) evaluating relugolix combination tablet for the prevention of pregnancy pending amendment of the study protocol to add bone mineral density monitoring. | brhc1002467_8k.htm |
| 2021-05-11 | 8-K | 2021-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2021, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months and full fiscal year ended March 31, 2021, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20210511.htm |
| 2021-02-11 | 8-K | 2021-02-11 | 2.02 Results of Operations and Financial Condition | 2.02 On February 11, 2021, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended December 31, 2020, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20210211.htm |
| 2021-01-04 | 8-K | 2021-01-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 4, 2021, David Marek joined Myovant Sciences Ltd. (the “Company”) as Principal Executive Officer and a member of the Board of Directors and also as Chief Executive Officer of its subsidiary, Myovant Sciences, Inc. (“Myovant”). | brhc10018576_8k.htm |
| 2020-12-28 | 8-K | 2020-12-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | myov-20201226.htm |
| 2020-12-18 | 8-K | 2020-12-18 | 8.01 Other Events | 8.01 On December 18, 2020, the U.S. Food and Drug Administration approved ORGOVYXTM (relugolix) as the first and only oral gonadotropin-releasing hormone (GnRH) therapy for the treatment of adult patients with advanced prostate cancer. | myov-20201218.htm |
| 2020-11-12 | 8-K | 2020-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2020, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended September 30, 2020, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20201112.htm |
| 2020-09-17 | 8-K | 2020-09-15 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On September 15, 2020, Myovant Sciences Ltd. (the “Company”) held its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) virtually at www.virtualshareholdermeeting.com/MYOV2020. | brhc10015142_8k.htm |
| 2020-08-11 | 8-K | 2020-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2020, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended June 30, 2020, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | myov-20200811.htm |
| 2020-08-05 | 8-K | 2020-08-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | brhc10014092_8k.htm |
| 2020-05-18 | 8-K | 2020-05-18 | 2.02 Results of Operations and Financial Condition | 2.02 On May 18, 2020, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months and full fiscal year ended March 31, 2020, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq4march312020myova.htm |
| 2020-05-08 | 8-K | 2020-05-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On May 4, 2020, Kim Sablich, Chief Commercial Officer of Myovant Sciences, Inc., advised Myovant Sciences Ltd. that she was resigning from her position to take on a senior executive role at a multinational pharmaceutical company. 8.01 Effective May 11, 2020, Adele Gulfo, Chief Business and Commercial Development Officer of Sumitovant Biopharma Inc. and board member of Myovant Sciences Ltd., will assume the role of interim Chief Commercial Officer, assuming commercial leadership responsibilities. | form8k.htm |
| 2020-02-10 | 8-K | 2020-02-10 | 2.02 Results of Operations and Financial Condition | 2.02 On February 10, 2020, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing recent corporate updates and announcing its financial results for the three months ended December 31, 2019, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq3december312019my.htm |
| 2019-12-30 | 8-K | 2019-12-21 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above under the caption “Loan Agreement” is incorporated by reference here. 2.04 The information set forth in Item 1.01 above under the caption “Loan Agreement” is incorporated by reference here. 3.03 The information set forth in Item 5.03 below is incorporated by reference here. 5.01 As described in Item 1.01 above, on December 27, 2019, at the Closing Sumitomo and Sumitovant Biopharma acquired from Roivant approximately 45,008,604 Common Shares, or 50.2% of the outstanding Common Shares, and as a result became a majority owner of Common Shares. 5.02 In connection with the transactions contemplated by the Investor Rights Agreement, on December 21, 2019 Vivek Ramaswamy, and on December 22, 2019 Frank Torti, M.D., resigned as directors of Myovant, contingent upon the Closing occurring. | form8k.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing corporate updates and announcing its financial results for the three months ended September 30, 2019, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq2september302019m.htm |
| 2019-10-31 | 8-K | 2019-10-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8k.htm |
| 2019-08-27 | 8-K | 2019-08-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On August 23, 2019, Myovant Sciences Ltd. (the “Company”) held its 2019 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. | form8k.htm |
| 2019-08-06 | 8-K | 2019-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2019, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing corporate updates and announcing its financial results for the three months ended June 30, 2019, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq1june302019myovant.htm |
| 2019-06-04 | 8-K | 2019-06-04 | 7.01 Regulation FD Disclosure | 7.01 On June 4, 2019, Myovant Sciences Ltd. closed its underwritten public offering of 17,424,243 common shares, including 2,272,727 common shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional common shares under the underwriting agreement with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC, and Evercore Group L.L.C., as representatives of the underwriters named therein. | d758632d8k.htm |
| 2019-05-31 | 8-K | 2019-05-30 | 8.01 Other Events | 8.01 On May 30, 2019, Myovant Sciences Ltd. (“Myovant”) entered into an underwriting agreement (“Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein, relating to the issuance and sale of 15,151,516 of Myovant’s common shares (the “Offering”) at a price to the public of $8.25 per share. | d754445d8k.htm |
| 2019-05-24 | 8-K | 2019-05-24 | 2.02 Results of Operations and Financial Condition | 2.02 On May 24, 2019, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing corporate updates and announcing its financial results for the three months and the full fiscal year ended March 31, 2019, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq4march312019myovant.htm |
| 2019-05-14 | 8-K | 2019-05-14 | 8.01 Other Events | 8.01 On May 14, 2019, Myovant Sciences Ltd. made available a slide presentation regarding the top-line results for its LIBERTY 1 Phase 3 clinical trial evaluating once daily relugolix combination therapy in women with uterine fibroids. | d744045d8k.htm |
| 2019-02-07 | 8-K | 2019-02-07 | 2.02 Results of Operations and Financial Condition | 2.02 On February 7, 2019, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing a corporate update and announcing its financial results for the three months ended December 31, 2018, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq3december312018myovant.htm |
| 2018-12-31 | 8-K | 2018-12-28 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 As previously disclosed, on October 16, 2017, Myovant Sciences Ltd. (the “Company”) and its subsidiaries entered into a Securities Purchase Agreement (the “NovaQuest Securities Purchase Agreement”) with the purchasers from time to time parties thereto (the “Purchasers”) and NovaQuest Pharma Opportunities Fund IV, L.P., in its capacity as administrative agent and collateral agent for itself and the Purchasers (“NovaQuest”), and the Company entered into an Equity Purchase Agreement (the “NovaQuest Equity Purchase Agreement”) with NovaQuest and a Purchaser affiliated with NovaQuest (the “NovaQuest Affiliate”). 3.02 The information in Item 2.03 above is incorporated by reference into this Item 3.02. | d669043d8k.htm |
| 2018-11-08 | 8-K | 2018-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2018, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing a corporate update and announcing its financial results for the three months ended September 30, 2018, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq2september302018myova.htm |
| 2018-09-24 | 8-K | 2018-09-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 19, 2018, Keith Manchester, MD resigned from the board of directors (the “Board”) of Myovant Sciences Ltd. (“Myovant”), effective on September 20, 2018. | a8-kitem502electionofadire.htm |
| 2018-09-04 | 8-K | 2018-08-31 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On August 31, 2018, Myovant Sciences Ltd. (the “Company”) held its 2018 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. | a8-kitem507submissionofmat.htm |
| 2018-08-07 | 8-K | 2018-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2018, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing a corporate update and announcing its financial results for the three months ended June 30, 2018, a copy of which is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. | a8-kq1june302018myovant.htm |
| 2018-07-24 | 8-K | 2018-07-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 23, 2018, the board of directors (the “Board”) of Myovant Sciences Ltd. (“Myovant”) appointed Mark Guinan as a member of the Board, effective immediately. | d550710d8k.htm |
| 2018-07-13 | 8-K | 2018-07-12 | 8.01 Other Events | 8.01 On July 12, 2018, Myovant Sciences Ltd. (“Myovant”) entered into an underwriting agreement (“Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Barclays Capital Inc., as representatives of the several underwriters named therein, relating to the issuance and sale of 3,333,334 of Myovant’s common shares (the “Offering”) at a price to the public of $22.50 per share. | d491749d8k.htm |
| 2018-07-10 | 8-K | 2018-07-10 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On July 10, 2018, Myovant Sciences Ltd. announced, in connection with its presentation at the first annual Roivant Pipeline Day (see item 7.01 below), that as of June 30, 2018, it had approximately $235.6 million in cash and committed funding, consisting of $143.6 million of cash and financing commitments totaling $92.0 million available to it from NovaQuest Capital Management. 7.01 On July 10, 2018, Lynn Seely, M.D., Principal Executive Officer of Myovant Sciences Ltd., will make a presentation regarding Myovant at the first annual Roivant Pipeline Day on July 10, 2018 at 2:30 p.m. 8.01 On July 10, 2018, Myovant Sciences Ltd. issued a press release titled “Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids.” In the press release Myovant announced: top-line data for its LIBERTY 1 trial is expected in the second quarter of 2019; Myovant is on track for top-line results from all relugolix Phase 3 clinical studies in uterine fibroids, endometriosis and prostate cancer during 2019; it completed the screening of patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating relugolix in women with heavy menstrual bleeding associated with uterine fibroids; it looks forward to completing LIBERTY 2 in its fiscal quarter ending September 30, 2018, and reporting top-line efficacy and safety data on LIBERTY 1 in the second quarter of 2019; it continues to work diligently towards top-line results on all of its ongoing Phase 3 clinical studies during 2019; and Myovant will be presenting at the first annual Roivant Pipeline Day on July 10, 2018 at 2:30 p.m. | d343641d8k.htm |
| 2018-06-07 | 8-K | 2018-06-07 | 2.02 Results of Operations and Financial Condition | 2.02 On June 7, 2018, Myovant Sciences Ltd. (the “Registrant”) issued a press release providing a corporate update and announcing its financial results for the three months and the full fiscal year ended March 31, 2018, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | a8-kq4march312018myovant.htm |
| 2018-06-05 | 8-K | 2018-05-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Effective as of May 30, 2018, Myovant Sciences GmbH (“MSG”), a wholly owned subsidiary of Myovant Sciences Ltd. (the “Company”), entered into a Commercial Manufacturing and Supply Agreement (the “Supply Agreement”) with Takeda Pharmaceutical Company Limited (“Takeda”) regarding relugolix. | d566002d8k.htm |
| 2018-04-04 | 8-K | 2018-04-04 | 3.02 Unregistered Sales of Equity Securities | 3.02 See Item 1.01 of the Current Report on Form 8-K filed by Myovant Sciences Ltd. (the “Company”) on April 3, 2018, which is incorporated by reference herein, regarding that certain share purchase agreement (the “Purchase Agreement”), dated April 2, 2018, with Roivant Sciences Ltd. (the “Purchaser”), pursuant to which the Company issued and sold to Purchaser 1,110,015 of its common shares at a purchase price of $20.27 per common share in a private placement (the “Private Placement”). | d563906d8k.htm |
| 2018-04-03 | 8-K | 2018-04-02 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d555202d8k.htm |
| 2018-03-30 | 8-K | 2018-03-26 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.03 As previously disclosed, on October 16, 2017, Myovant Sciences Ltd. (the “Company”) and its wholly-owned subsidiaries, Myovant Holdings Limited (“MHL”), Myovant Sciences GmbH (“MSG”), Myovant Sciences, Inc. (“MSI”) and Myovant Sciences Ireland Limited (“MSIL”, together with MHL, MSG and MSI, the “Guarantors” and the Guarantors and the Company, collectively, the “Loan Parties”), entered into a Loan and Security Agreement (the “Hercules Loan Agreement”) with the lenders from time to time party thereto (the “Lenders”) and Hercules Capital, Inc., as agent for itself and the Lenders (“Hercules”). 3.02 In connection with the March Term Loan, the Company issued to Hercules a warrant (the “Warrant”) to purchase a number of the Company’s common shares equal to 3% of the principal amount of the March Term Loan divided by the exercise price, which was based on the lowest three day volume-weighted average price for the three consecutive trading days prior to the funding date for the March Term Loan. 5.02 analysis conducted by the Compensation Committee’s independent consultant. | d539276d8k.htm |
| 2018-03-22 | 8-K | 2018-03-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 21, 2018, Wayne DeVeydt, a member of the Board of Directors (the “Board”) of Myovant Sciences Ltd. (the “Company”), notified the Board that, as a result of his new position as Chief Executive Officer of Surgery Partners, Inc., a publicly traded company on the Nasdaq Global Select Market, he does not intend to stand for reelection at the Company’s 2018 Annual General Meeting of Shareholders (the “Annual Meeting”). | d556462d8k.htm |
| 2018-02-13 | 8-K | 2018-02-13 | 2.02 Results of Operations and Financial Condition | 2.02 On February 13, 2018, Myovant Sciences Ltd. (the “Registrant”) issued a press release announcing its financial results for the three and nine months ended December 31, 2017. | a1231178-k.htm |
| 2018-02-09 | 8-K | 2018-02-09 | 3.03 Material Modification to Rights of Security Holders; 5.07 Submission of Matters to a Vote of Security Holders | 3.03 The information set forth in Item 5.07 is incorporated herein by reference. 5.07 On February 9, 2018, Myovant Sciences Ltd. (the “Company”) held a Special General Meeting of Shareholders (the “Special Meeting”) in London, United Kingdom. | d513530d8k.htm |
| 2017-11-13 | 8-K | 2017-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2017, Myovant Sciences Ltd. (the “Registrant”) issued a press release announcing its financial results for the three and six months ended September 30, 2017. | a930178-k.htm |
| 2017-10-16 | 8-K | 2017-10-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information in Item 1.01 above relating to the NovaQuest Securities Purchase Agreement and the Hercules Loan Agreement is incorporated by reference into this Item 2.03. 3.02 The information in Item 1.01 above relating to the NovaQuest Securities Purchase Agreement, the NovaQuest Equity Purchase Agreement and the Warrants is incorporated by reference into this Item 3.02. | d475431d8k.htm |
| 2017-08-23 | 8-K | 2017-08-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On August 18, 2017, Myovant Sciences Ltd. (the “Company”) held its 2017 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. | d429208d8k.htm |
| 2017-08-10 | 8-K | 2017-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2017, Myovant Sciences Ltd. (the “Registrant”) issued a press release announcing its financial results for the three months ended June 30, 2017. | a630178-k.htm |
| 2017-04-27 | 8-K/A | 2017-03-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 28, 2017, the Compensation Committee of the Board of Directors (the “Board”) of the Registrant approved the annual base salary and bonus target opportunity effective April 1, 2017 for Dr. Seely, the Registrant’s Principal Executive Officer. | d385479d8ka.htm |
| 2017-04-03 | 8-K | 2017-03-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 28, 2017, the Compensation Committee of the Board of Directors (the “Board”) of Myovant Sciences Ltd. (the “Registrant”) approved the annual cash bonus for the fiscal year ended March 31, 2017 and the annual base salary and bonus target opportunity effective April 1, 2018 for Lynn Seely, the Registrant’s Principal Executive Officer. | d258162d8k.htm |
| 2016-11-17 | 8-K | 2016-11-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 15, 2016, the Board of Directors (the “Board”) of Myovant Sciences Ltd. (the “Company”) appointed Terrie Curran to serve as a director of the Company, effective immediately. | d296727d8k.htm |
| 2016-11-03 | 8-K | 2016-11-01 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 Effective as of November 1, 2016, Myovant Sciences Ltd. (the “Registrant”) adopted the Second Amended and Restated Bye-laws of the Registrant (the “Restated Bye-laws”) in connection with the closing of the Registrant’s initial public offering of its common shares (the “IPO”) effected pursuant to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-213891). | d293801d8k.htm |